These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8410074)

  • 41. Myasthenia gravis: an autoimmune response against the acetylcholine receptor.
    Graus YM; De Baets MH
    Immunol Res; 1993; 12(1):78-100. PubMed ID: 7685805
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Myasthenia gravis: T and B cell reactivities to the beta-bungarotoxin binding protein presynaptic membrane receptor.
    Link H; Sun JB; Lu CZ; Xiao BG; Fredrikson S; Höjeberg B; Olsson T
    J Neurol Sci; 1992 Jun; 109(2):173-81. PubMed ID: 1634899
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Seronegative myasthenia gravis.
    Vincent A; McConville J; Farrugia ME; Newsom-Davis J
    Semin Neurol; 2004 Mar; 24(1):125-33. PubMed ID: 15229799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myasthenia gravis, a model of organ-specific autoimmune disease.
    Berrih-Aknin S
    J Autoimmun; 1995 Apr; 8(2):139-43. PubMed ID: 7612144
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
    Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
    J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of alpha-bungarotoxin binding to acetylcholine receptors by antisera from animals with experimental autoimmune myasthenia gravis.
    Claudio T; Raftery MA
    J Supramol Struct; 1980; 14(3):267-79. PubMed ID: 6971372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of an assay for modulating anti-acetylcholine receptor autoantibodies using human rhabdomyosarcoma cell line.
    Lyons BW; Wu LL; Astill ME; Wu JT
    J Clin Lab Anal; 1998; 12(5):315-9. PubMed ID: 9773965
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms of acetylcholine receptor loss from the neuromuscular junction.
    Engel AG; Fumagalli G
    Ciba Found Symp; 1982; (90):197-224. PubMed ID: 6923808
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pseudo-internuclear ophthalmoplegia in myasthenia gravis].
    Bogdan I; Crisanda V
    Oftalmologia; 2011; 55(3):70-3. PubMed ID: 22428294
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibodies from myasthenic patients that compete with cholinergic agents for binding to nicotinic receptors.
    Fulpius BW; Miskin R; Reich E
    Proc Natl Acad Sci U S A; 1980 Jul; 77(7):4326-30. PubMed ID: 6933485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Autoantibodies detected in acetylcholine receptor antibody-negative myasthenia gravis].
    Ohta R; Motomura M
    Rinsho Byori; 2014 Mar; 62(3):255-60. PubMed ID: 24800501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Region of peptide 125-147 of acetylcholine receptor alpha subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies.
    Lennon VA; McCormick DJ; Lambert EH; Griesmann GE; Atassi MZ
    Proc Natl Acad Sci U S A; 1985 Dec; 82(24):8805-9. PubMed ID: 3878521
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-agrin autoantibodies in myasthenia gravis.
    Gasperi C; Melms A; Schoser B; Zhang Y; Meltoranta J; Risson V; Schaeffer L; Schalke B; Kröger S
    Neurology; 2014 Jun; 82(22):1976-83. PubMed ID: 24793185
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Experimental autoimmune myasthenia gravis: can pretreatment with 125I-labeled receptor prevent functional damage at the neuromuscular junction?
    Sterz RK; Biro G; Rajki K; Filipp G; Peper K
    J Immunol; 1985 Feb; 134(2):841-6. PubMed ID: 2578165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Refractoriness to a second episode of experimental myasthenia gravis. Correlation with AChR concentration and morphologic appearance of the postsynaptic membrane.
    Corey AL; Richman DP; Agius MA; Wollmann RL
    J Immunol; 1987 May; 138(10):3269-75. PubMed ID: 3494763
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathogenesis of hyperacute experimental autoimmune myasthenia gravis. Acetylcholine receptor/cholinergic site/receptor function/autoimmunity.
    Mihovilovic M; Donnelly-Roberts D; Richman DP; Martinez-Carrion M
    J Immunol; 1994 Jun; 152(12):5997-6002. PubMed ID: 8207224
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of antibodies directed against the cytoplasmic region of the human acetylcholine receptor in sera from myasthenia gravis patients.
    Tzartos SJ; Remoundos M
    Clin Exp Immunol; 1999 Apr; 116(1):146-52. PubMed ID: 10209519
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interaction of myasthenic immunoglobulins and cholinergic agonists on acetylcholine receptors of rat myotubes.
    Ashizawa T; Elias SB; Appel SH
    Ann Neurol; 1982 Jan; 11(1):22-7. PubMed ID: 6277235
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis.
    Howard FM; Lennon VA; Finley J; Matsumoto J; Elveback LR
    Ann N Y Acad Sci; 1987; 505():526-38. PubMed ID: 3479935
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A practical enzyme immunoassay for anti-acetylcholine receptor antibodies in myasthenia gravis.
    Furukawa S; Akazawa S; Furukawa Y; Kamo I; Satoyoshi E; Hayashi K
    J Neuroimmunol; 1984; 6(6):397-409. PubMed ID: 6384263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.